Search company, investor...

Eutropics

eutropics.com

Stage

Debt | Alive

Total Raised

$8.94M

Last Raised

$350K | 1 yr ago

About Eutropics

Eutropics is a biomarker discovery and clinical diagnostics laboratory that develops functional clinical diagnostic tests that recognize unique features of cancer cells from individual patients.

Headquarters Location

767-C Concord Avenue

Cambridge, Massachusetts, 02138,

United States

617-714-4405

Missing: Eutropics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Eutropics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Eutropics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Eutropics is included in 2 Expert Collections, including Cancer.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

B

Biopharma Tech

838 items

Eutropics Patents

Eutropics has filed 22 patents.

The 3 most popular patent topics include:

  • Oncology
  • Transcription factors
  • Acid fast bacilli
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/24/2020

12/6/2022

Autoimmune diseases, Nontuberculous mycobacteria, Acid fast bacilli, Oncology, Cancer treatments

Grant

Application Date

3/24/2020

Grant Date

12/6/2022

Title

Related Topics

Autoimmune diseases, Nontuberculous mycobacteria, Acid fast bacilli, Oncology, Cancer treatments

Status

Grant

Latest Eutropics News

Eutropics' PraediCare Dx™ Noxa Biomarker Driven Clinical Study Data Presented at the 23rd Annual Congress of the European Hematology Association (EHA)

Jun 19, 2018

Share this article CAMBRIDGE, Mass., June 19, 2018 /PRNewswire/ -- At last week's EHA meeting, Tolero Pharmaceuticals, Inc. presented positive data in patients treated with alvocidib, a cyclin-dependent kinase (CDK) inhibitor class drug, in combination with standard of care for acute myeloid leukemia: Zeidner, et al., "Phase II Study Incorporating a Novel BH3-Profiling Biomarker Approach of Alvocidib Followed by Cytarabine and Mitoxantrone in Relapsed/Refractory Acute Myeloid Leukemia (AML)," EHA23, Abstract PF243. The trial design relied on selecting patients using a novel functional biomarker. Eutropics' PraediCare Dx™ Noxa test provided the patient sample readout that revealed dependence on the anti-apoptotic protein MCL1. The data from the trial indicates that a majority of patients selected using Eutropics' PraediCare Dx™ Noxa test achieved complete remission. Encouraged by the improved response rates in selected patients Tolero announced that they will continue their Phase 2 study on alvocidib in patients with relapsed and refractory, MCL1-dependent AML. PraediCare Dx™ accurately measures this dependence of malignant cells in a unique way that identifies what is termed the "Noxa primed state." Recent studies have shown that in addition to identifying alvocidib responsiveness, the occurrence of the Noxa primed state identifies patients who are most likely to respond to a range of MCL1 perturbing cancer therapies. This important biomarker is being further assessed for use in guiding such cancer treatments. "We believe that the correlation between the PraediCare Dx™-measured drug target function and clinical response to treatment can greatly benefit AML patients, both by speeding clinical development of alvocidib and other drugs in this class and by directing the most efficacious use of these drugs after they are approved," said Michael Cardone, Ph.D., CEO of Eutropics. About PraediCare Dx™ Based on the fundamental principles of apoptosis biology and derived from the BH3 profiling methodology, PraediCare Dx™ provides uniquely accurate predictive functional biomarkers for AML, multiple myeloma and CLL. The PraediCare Dx™ Noxa assay was developed for CDK inhibitor class drugs and for other MCL1 targeting therapies. The platform has applicability to other targeted therapies, including BH3 mimetics. About Eutropics Eutropics is a clinical diagnostics company developing a novel approach for guiding cancer treatment, enabling the delivery of personalized medicines to patients. Eutropics' PraediCare Dx™ platform technology delivers medically useful in vitro diagnostics accelerating drug development including Eutropics' compounds. Contact: Anne Assm

Eutropics Frequently Asked Questions (FAQ)

  • Where is Eutropics's headquarters?

    Eutropics's headquarters is located at 767-C Concord Avenue, Cambridge.

  • What is Eutropics's latest funding round?

    Eutropics's latest funding round is Debt.

  • How much did Eutropics raise?

    Eutropics raised a total of $8.94M.

  • Who are the investors of Eutropics?

    Investors of Eutropics include MassVentures and National Institutes of Health.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.